Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RXRX vs DGNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RXRX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–2 Matrix Metrics)

RXRX Overall Winner 6-Pillar Tally: RXRX 4 – 2 DGNX Matrix Metrics: RXRX 5 – 2 DGNX

As of Nov 16, 2026, Recursion Pharmaceuticals, Inc. (RXRX) is the stronger overall head-to-head candidate over Diginex Limited (DGNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RXRX carries a Unified Composite Score of 49.5/100 (HOLD) at $2.90 (N/M Forward P/E, -734.2% operating margin), whereas DGNX carries 49.7/100 (HOLD) at $1.18 (N/M Forward P/E, -546.3% operating margin).

  • Technical & Structure Timing Caution: RXRX is currently in a Breakdown options structure phase (RSI 35.7); meanwhile DGNX is in a Breakdown options structure phase (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RXRX vs DGNX
RXRX NASDAQ Head-to-Head Winner
Recursion Pharmaceuticals, Inc. Class A Common Stock
Biological Products, (No Disgnostic Substances)
$2.90
-8.79% 1D
Market Cap $2.1B
TTM Revenue $68M
Forward P/E N/M
Beta / 30D Vol 3.01β · 85% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.7 · SMA20: $3.69 · SMA50: $3.77
DGNX NASDAQ
Diginex Limited Ordinary Shares
Services-Computer Processing & Data Preparation
$1.18
-7.81% 1D
Market Cap $63.7M
TTM Revenue $3.6M
Forward P/E N/M
Beta / 30D Vol 0.04β · 100% Vol
Unified Composite Score
49.7 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $1.31 · SMA50: $1.33

6-Pillar Scorecard Institutional Category Breakdown (RXRX 4 – 2 DGNX)

Columns: Metric · RXRX · DGNX
1. Valuation Multiples DGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 23.5x 17.6x
2. Growth & Scale RXRX
Revenue Growth (YoY) +258.5% +3.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $68M $3.6M
Market Cap $2.1B $63.7M
3. Profitability & Quality DGNX
Gross Margin N/A 100.0%
Operating Margin -734.2% -546.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -48.7% -250.4%
4. Balance Sheet & Cash Flow RXRX
Cash Generation (TTM) -$314M -$19M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $475M Net Cash $0.70 Book/Sh · -250.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RXRX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 92.3% (61st %ile) 392.0% (51st %ile)
Put/Call OI Skew 0.58x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RXRX
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RXRX (5) vs DGNX (2)
Institutional Metric RXRX DGNX Criterion Row Edge
Market Capitalization
Scale
$2.1B $63.7M Larger Scale RXRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+258.5% +3.3% Higher Growth RXRX
Operating Margin (TTM)
Profitability
-734.2% -546.3% Higher Margin DGNX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-48.7% -250.4% Higher ROE RXRX
52-Week Range Position
Momentum
6% ($3–$5) 4% ($0–$18) Stronger Trend RXRX
Beta / 30D Volatility
Risk Regime
3.01β · 85% Vol 0.04β · 100% Vol Lower Realized Risk RXRX
Unified Institutional Score
Composite Signal
49.5 / 100 (HOLD) 49.7 / 100 (HOLD) Higher Composite DGNX
Trailing 12M Revenue (USD)
Operating Scale
$68M $3.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 23.5x EV/Rev N/M PEG · 17.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$314M ($475M Net Cash) -$19M EBITDA ($0.70 Book/Sh · -250.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DGNX +16.16 pp
RXRX: -16.16% · DGNX: +0.0%
3M Horizon DGNX +1.15 pp
RXRX: -5.99% · DGNX: -4.84%
6M Horizon DGNX +24.87 pp
RXRX: +0.52% · DGNX: +25.39%
1Y Horizon RXRX +58.35 pp
RXRX: -32.91% · DGNX: -91.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RXRX vs DGNX. Trailing 12-month operating profitability (RXRX -734.2% vs DGNX -546.3%) and valuation multiples (RXRX N/M vs DGNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RXRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$68M
Gross MarginN/A
Op. Margin-734.2%
ROE / Fwd P/E-48.7% · N/M
DGNX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.6M
Gross Margin100.0%
Op. Margin-546.3%
ROE / Fwd P/E-250.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RXRX BREAKDOWN
30d in phase · OBV DISTRIBUTION
Current IV 92.3%
IV Percentile 61st %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact RXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DGNX BREAKDOWN
140d in phase · OBV NEUTRAL
Current IV 392.0%
IV Percentile 51st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RXRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -734.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · AI Drug Discovery
DGNX Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $63.7M market capitalization and -546.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RXRX vs DGNX Key Questions & Quantitative Answers

As of Nov 16, 2026, Recursion Pharmaceuticals, Inc. (RXRX) is the stronger overall head-to-head candidate over Diginex Limited (DGNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RXRX carries a Unified Composite Score of 49.5/100 (HOLD) at $2.90 (N/M Forward P/E, -734.2% operating margin), whereas DGNX carries 49.7/100 (HOLD) at $1.18 (N/M Forward P/E, -546.3% operating margin). Technical & Structure Timing Caution: RXRX is currently in a Breakdown options structure phase (RSI 35.7); meanwhile DGNX is in a Breakdown options structure phase (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RXRX leads the Growth & Scale pillar: RXRX posts +258.5% YoY revenue growth and +0.0% YoY earnings growth on $68M TTM revenue (N/A gross margin, -734.2% operating margin), compared with DGNX at +3.3% YoY revenue growth and +0.0% YoY earnings growth on $3.6M TTM revenue (100.0% gross margin, -546.3% operating margin). On trailing 12-month operating scale, RXRX generates $68M in USD-normalized revenue versus $3.6M for DGNX. In operating R&D and SG&A reinvestment, RXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DGNX.

DGNX screens cheaper on headline valuation multiples. RXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 23.5x EV/Revenue (unreported FCF margin), whereas DGNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RXRX (-48.7% ROE) versus DGNX (-250.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RXRX carries 92.3% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 85% Vol realized risk). By comparison, DGNX carries 392.0% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.04β · 100% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.